Fabien Dépis is the Director of Discovery Research at Gentibio. Fabien is an immunologist by training with a strong background in immunotherapies and early drug development, expert in targeting Regulatory T (Treg) cells in autoimmunity and immuno-oncology settings. Prior to Gentibio, he held multiple positions with increasing leadership responsibilities in Discovery. During his industrial PhD at NovImmune SA (now Light Chain Bioscience), Fabien published several articles and filed multiple patent applications combining use of anti-CD3 mAbs and other anti-proinflammatory cytokines mAbs to manipulate Treg/Teff cell balance in autoimmune diseases. He completed his post-doctoral fellowship in the laboratory of Diane Mathis and Christophe Benoist at Harvard Medical School, focusing on Treg biology. Fabien initiated the first immunotherapy program (MM-401) at Merrimack Pharmaceuticals; most recently at Jounce Therapeutics, he led JTX-1811 program team (anti-CCR8 mAb, depleting tumor Tregs in IO), from target inception to IND-enabling stage, leading to its exclusive licensing by Gilead in September 2020 (now GS-1811, currently in clinical trial). Fabien comes most recently from Celsius Therapeutics where he helped as interim co-lead of the IBD Discovery group. Aside from his passion for Tregs, Fabien enjoys fishing and playing soccer.
Fabien Dépis, PhD
Director, Discovery Research